16 January 2026
: Case report
A 17-Year-Old Male Adolescent With Refractory Crohn’s Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence
Unusual or unexpected effect of treatment
Mohammad Alhashemi BCDEF 1, Mohammad ShehabDOI: 10.12659/AJCR.950174
Am J Case Rep 2026; 27:e950174
Figure 1 Images taken before the start of upadacitinib and risankizumab: (A) the rectum; (B) the ascending colon; (C) the terminal ileum, with multiple medium-sized deep ulcers with surrounding edema, erythema, and skip lesions; and (D) the cecum, with multiple medium-sized deep ulcers with surrounding edema, erythema, and skip lesions.






